Alligator Bioscience Sees Revenue Upside as Henlius Advances HLX22 into Phase 2/3 Breast Cancer Trial

Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an announcement.

Alligator Bioscience has highlighted progress at partner Shanghai Henlius Biotech, which has dosed the first patient in a Phase 2/3 trial of HLX22 combined with antibody-drug conjugate HLX87 in first-line HER2-positive recurrent or metastatic breast cancer in China. HLX22, an innovative anti-HER2 monoclonal antibody with orphan drug designation in the U.S. and EU for gastric cancer, is being developed by Henlius under a license from AbClon in which Alligator holds rights to participate in future revenues.

Alligator underscored that Henlius is advancing HLX22 across multiple indications with several parallel clinical trials, signaling strategic commitment and confidence in the molecule’s clinical and commercial potential. Under its agreement with AbClon, Alligator is entitled to 35% of AbClon’s revenue from the Henlius sublicense, including potential milestones and royalties, which could translate into a meaningful long-term revenue stream for Alligator if HLX22 is successfully developed and approved.

The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.16 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.

More about Alligator Bioscience AB

Alligator Bioscience is a Swedish biotechnology company developing clinical-stage, tumor-directed antibody drugs focused on the CD40 receptor in immuno-oncology. Its lead candidate, mitazalimab, is ready for Phase 3 development and has shown strong 30‑month survival data in first-line metastatic pancreatic cancer patients in the Phase 2 OPTIMIZE-1 trial.

YTD Price Performance: -40.77%

Average Trading Volume: 4,671,224

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK106.6M

Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.